Farmas USA

joder, tienes toda la razon. y por mucho que lo leyera seguia viendo "Vacespa".
lo que es la mente.
thanks :)

Un equipo de médicos de la Universidad de Mississipi aseguran haber curado a un bebé que nació con VIH.
Geniales noticias.
La noticia aparece en casi todos, por no decir en todos los medios por si lo queréis leer más en detalle.

ARNA, resultados financieros...:
"Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q4 GAAP loss of $0.10 per share, which may not compare to the analyst estimate of ($0.03). Revenue for the quarter came in at $1.94 million, versus the consensus estimate of $21.94 million.
In the same period last year, Arena reported revs of $2.08 million and a loss of $0.16 per share.

In addition to revenue from BELVIQ sales, Arena expects revenues of $65 million in milestone payments from Eisai"
.
Más info: http://www.streetinsider.com/Earnings/UPDATE%3A+Arena+Pharmaceuticals+%28ARNA%29+Narrows+Q4+GAAP+Loss+to+10cShare/8150050.html

Al loro hoy si lleváis algo de este tipo. Ha salido un estudio que dice que los tratamientos con incretinas aumentan el riesgo de pancreatitis aguda.

ARNA

Espero comentarios

Fourth Quarter and Full Year 2012 Financial Results

Arena recorded revenues totaling $1.9 million in the fourth quarter of 2012, compared to $2.1 million in the fourth quarter of 2011, and $27.6 million in the full year ended December 31, 2012, compared to $12.7 million in the full year ended December 31, 2011. The revenue increase in the full year ended December 31, 2012, was primarily due to the $20.0 million milestone payment from Eisai for the inclusion of the efficacy and safety data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) clinical trial in the FDA-approved prescribing information for BELVIQ.

Research and development expenses increased to $13.9 million in the fourth quarter of 2012 from $13.1 million in the fourth quarter of 2011. Research and development expenses in the full year ended December 31, 2012, declined to $54.1 million from $58.7 million in the full year ended December 31, 2011. These decreases were primarily attributable to decreases in internal research and development manufacturing costs related to our Swiss manufacturing facility and decreased salary and other personnel costs. General and administrative expenses increased to $7.3 million in the fourth quarter of 2012, compared to $5.3 million in the fourth quarter of 2011, and $26.2 million in the full year ended December 31, 2012, compared to $24.2 million in the full year ended December 31, 2011. These increases were primarily attributable to higher share-based compensation and salary and other personnel costs.

Total interest and other expense in the fourth quarter of 2012 decreased to $1.0 million, compared to $5.4 million in the fourth quarter of 2011. Total interest and other expense in the full year ended December 31, 2012, increased to $28.4 million, compared to $26.4 million in full year ended December 31, 2011. This expense increase in the full year ended December 31, 2012, was primarily due to recognition of a $13.4 million non-cash loss from revaluation of derivative liabilities, partially offset by a $5.2 million decrease in interest expense related to the payoff in May 2012 of Arena's former loan with Deerfield and a $4.2 million decrease in the non-cash loss on extinguishment of debt. Arena's net loss allocable to common stockholders in the full year ended December 31, 2012, was $88.3 million, or $0.45 per share, compared to $111.5 million, or $0.80 per share, in the full year ended December 31, 2011.

At December 31, 2012, cash and cash equivalents totaled $156.1 million and approximately 217.5 million shares of common stock were outstanding.

2013 Financial Guidance

In addition to revenue from BELVIQ sales, Arena expects revenues of $65 million in milestone payments from Eisai following the DEA's final scheduling of BELVIQ, approximately $6 million from amortization of upfront payments from existing collaborations, approximately $3 million from manufacturing services from Siegfried, and $1.5 million from additional regulatory milestone payments from Eisai. Arena expects full year 2013 research and development expenses of approximately $70 million to $78 million, including non-cash expenses of approximately $7 million, and general and administrative expenses of approximately $28 million to $34 million, including non-cash expenses of approximately $6 million.

ARNA

Activo: 262.206 (2012) vs. 157.129 (2011)
Pasivo: 261.206 (2012) vs. 157.129 (2011)

Qué manera de cuadrar las cosas.

http://invest.arenapharm.com/secfiling.cfm?filingid=1193125-13-88738

ARNA

La andan moviendo en el pre. 15.700 acciones y -1,92%. Último precio 8,18.

Edito: había multiplicado las acciones x 1000

HEB

Le aprueban la inyección de alferón en Argentina y está subiendo un 14,87 en pre con un volumen de 8.800

Edito: había multiplicado las acciones x 1000